tbuckley/cabot-search huggingface dataset:
Physical Activity in Pediatric Pulmonary Arterial Hypertension Measured by Accelerometry. A Candidate Clinical Endpoint
Authors: Willemijn M. H. Zijlstra, Mark-Jan Ploegstra, Theresia Vissia-Kazemier, Marcus T. R. Roofthooft, Gideon du Marchie Sarvaas, Beatrijs Bartelds, Annette Rackowitz, Freek van den Heuvel, Hans L. Hillege, Guy Plasqui, Rolf M. F. Berger
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: The development of evidence-based treatment guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lack of pediatric clinical trials. Trial design is hampered by lack of a feasible clinical endpoint in this population.Objectives: To evaluate the use of accelerometry for measuring physical activity (PA) in pediatric PAH and to investigate its correlation with clinical disease severity markers.Methods: We included children from the Dutch National Network for Pediatric Pulmonary Hypertension. Control patients were recruited from the outpatient cardiology clinic of the Beatrix Children's Hospital. Children were asked to wear the accelerometer for 7 days. Vector magnitude counts per minute (VM CPM) and time per day spent in different PA intensity levels were defined as accelerometer outcomes.Measurements and Main Results: VM CPM was lower in children with PAH (n = 29) than in controls (n = 60; 647 vs. 921; P < 0.001). Children with PAH spent less time in moderate and vigorous PA (13 vs. 29 min/d and 2 vs. 13 min/d, respectively; P < 0.001). Time spent in moderate and vigorous PA correlated inversely with World Health Organization functional class. Time spent in moderate PA correlated positively with 6-minute-walk distance. In post hoc analyses, VM CPM and time spent in moderate/vigorous combined and vigorous PA were associated with outcome (P ≤ 0.044).Conclusions: PA is markedly decreased in children with PAH. Accelerometer output correlated with clinical disease severity markers and may predict outcome. We showed an exciting potential of PA as a meaningful endpoint for clinical trials in pediatric PAH, although its clinical utility and prognostic value need to be further validated.
Another Case of Interleukin-2 Receptor Alpha Chain (IL2RA) Deficiency
Authors: Danilo Gois Goncalves, Larissa Prando Cau, Pâmella Diogo Salles, Paula Quadros Marques, Mariele Morandin Lopes, Claudia Leiko Yonekura Anagusko, Leonardo Oliveira Mendonca, Myrthes Toledo Barros
Journal: Journal of Allergy and Clinical Immunology (2017)
Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study
Authors: Parinda A. Mehta, Stella M. Davies, Thomas Leemhuis, Kasiani Myers, Nancy A. Kernan, Susan E. Prockop, Andromachi Scaradavou, Richard J. O’Reilly, David A. Williams, Leslie Lehmann, Eva Guinan, David Margolis, K. Scott Baker, Adam Lane, Farid Boulad
Journal: Blood (2017)
Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?
Authors: Sara Farshchi-Zarabi, Gurdeep Parmar, Esther Masih-Khan, Sophia Farooki, Christine Chen, Vishal Kukreti, Anca Prica, Rodger Tiedemann, Suzanne Trudel, Donna Reece
Journal: Blood (2015)
Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome
Authors: Leejah Chang, Susan Price, Katie Perkins, Joie Davis, Patricia Aldridge, Michael Recht, John Kelleher, V. Koneti Rao
Journal: Blood (2011)
Significant Cognitive Function Impairment in Association with Sleep Disruption in Patients with Chronic Rhinosinusitis (CRS)
Authors: Ferry Gunawan, Jessica W. Hui, Arpita Mehta, Mary C. Tobin, Sindhura Bandi, Pete S. Batra, Phillip S. LoSavio, Mahboobeh Mahdavinia
Journal: Journal of Allergy and Clinical Immunology (2017)
Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials.
Authors: Maria Clemence Schwaederle, Melissa M. Zhao, J. Jack Lee, Alexander Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2015)

11097 Background: The benefit of a personalized cancer treatment strategy (matching patients with drugs based on specific biomarkers) is still a matter of debate. We performed a systematic review and meta-analysis of recently published phase II studies in order to compare outcomes between arms that adopted a biomarker-based approach and those that did not. Methods: This analysis included 570 phase II studies (641 single-agent arm(s); 32,149 patients) (January 1st, 2010 to December 31st, 2012; Pubmed search). A weighted pooled analysis and a meta-analysis were performed. Response rate (RR), progression-free survival (PFS), overall survival (OS), and death rate were compared for treatment arms that used a personalized strategy versus those that did not. Results: Personalized arms (N = 112) accrued 8,078 patients compared to 24,071 patients for non-personalized arms (N = 529 arms). Multivariable analysis (both weighted multiple linear regression and random effect meta-regression) demonstrated that the personalized approach consistently and independently correlated with higher RR (31% vs 10.5%, P < 0.0001), prolonged median PFS (5.9 vs 2.7 months, P < 0.0001) and OS (13.7 vs 8.9 months, P = 0.0001). Non-personalized targeted arms (i.e., targeted agent without biomarker selection) had poorer outcomes compared to either personalized targeted therapy or cytotoxics (211/212 cytotoxic arms were non-personalized): RR 4, 30 and 11.9%, respectively; median PFS, 2.6, 6.9, and 3.3 months (all P < 0.0001); and OS, 8.7, 15.9, and 9.4 months (all P ≤ 0.05), respectively. Personalized arms using a “genomic biomarker” had higher RR and longer PFS and OS (all P < 0.05) than those using a “protein biomarker”. A lower treatment-related death rate was observed in personalized arms (1.5% vs 2.3%, P = 0.0008). Conclusions: Comprehensive analysis of Phase II, single agent arms revealed that, across malignancies, a personalized strategy was an independent predictor of better outcomes and fewer toxic deaths. In addition, non-personalized targeted arms were associated with significantly poorer outcomes than cytotoxic agents, which in turn were worse than personalized targeted therapy.
"Hot Girls Pearls" and other coping strategies for women experiencing adverse effects from endocrine therapy in the treatment of breast cancer.
Authors: Meghan Halley, Louise Beryl, Katherine Gillespie, Katharine Rendle, Suepattra Grace May, Domnick L Frosch
Journal: Journal of Clinical Oncology (2016)

197 Background: While endocrine therapy can significantly improve outcomes for women with hormone receptor-positive breast cancer, as few as 50% of patients take the medication as prescribed. Studies have shown that physical side effects contribute to non-adherence with hormone therapy. This study draws on prospective, qualitative interviews with patients to identify coping strategies patients employ to manage concerns over current and anticipated side effects, and suggests methods for encouraging adherence. Methods: Interviews were conducted with breast cancer patients (n = 41) at four time points throughout their treatment, resulting in over 150 patient narratives. Using a grounded theory approach, data were coded and analyzed to identify influential factors in decision-making. Here we present data from a subset of our participants (n = 18) focused on the role of side effects in patients' endocrine therapy decision-making. Results: Patients expressed a variety of concerns about current and anticipated side effects associated with endocrine therapy. Our data suggest five categories of coping strategies participants employed to manage these concerns: 1) emphasizing control over their choice to remain adherent; 2) focusing on a future free from side effects and cancer instead of current concerns or discomfort; 3) "familiarizing" side effects to make current and potential treatment risks feel less strange and/or intimidating; 4) making lifestyle changes to mitigate physical discomfort; and 5) seeking help from both medical and social sources. Patients often described using these multiple strategies to help navigate the functional, social and physical responses to side effects, and remain adherent to their treatment regimen. Conclusions: Our data describe the diverse coping strategies employed by women to manage current or anticipated side effects, and maintain adherence to prescribed endocrine therapy. Discussion of these different coping strategies by clinicians with patients may help to improve adherence rates by personalizing approaches to managing side effects.
A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS.
Authors: Jorge Cortes, Gail J. Roboz, Hagop Kantarjian, Eric Feldman, Judy Karp, Allyson Pollack, Katrina Sandy, Niranjan Rao, Shiro Akinaga, Mark Levis
Journal: Blood (2007)
High BMP2 Expression Is a Poor Prognostic Factor and a Good Candidate to Identify CBFA2T3-GLIS2-like High-Risk Subgroup in Pediatric Acute Myeloid Leukemia
Authors: Yusuke Hara, Genki Yamato, Norio Shiba, Kentaro Ohki, Myoung-Ja Park, Daisuke Tomizawa, Tomohiko Taki, Takashi Taga, Hirokazu Arakawa, Akio Tawa, Keizo Horibe, Souichi Adachi, Yasuhide Hayashi
Journal: Blood (2015)
Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients. Impact on biomarker testing
Authors: A. Romero, I. Nieto-Alcolado, C. Jiménez-Sánchez, V. Calvo de Juan, L. Gutierrez, M. Palka Kotlowska, M. Provencio, M. Torrente
Journal: Annals of Oncology (2016)
Bone Scan, PET-CT, and MRI in Disseminated Coccidioidomycosis
Authors: John Randolph Dryden, Michael David Starsiak, Mickaila James Johnston, Eugene David Silverman
Journal: Clinical Nuclear Medicine (2017)

Coccidioidomycosis (valley fever) is a systemic fungal infection resulting from inhalation of the Coccidioides immitis or posadasii spores. In many cases, infection causes a self-limited community-acquired pneumonia; however, in patients with risk factors, such as immunosuppression or African or Pacific Island ancestry, significant morbidity and mortality from disseminated disease may occur. Presented here are comparative images using Tc-MDP bone scan, F-FDG PET/CT, and MRI. Each demonstrates particular strengths, which aid in assessing the extent of systemic involvement of a biopsy-proven case of disseminated coccidioidomycosis.
40P Effect of ABCB1 and SLC22A16 genes polymorphism in outbreak of doxorubicin-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian breast cancer patients
Authors: A. Faraji, H. Dehghan Manshadi, M. Mobaraki, M. Zare, Z. Siavashpour, M. Houshmand
Journal: Annals of Oncology (2016)
Erratum: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma (Cancer Research (October 1, 2004) 64 (6883-6891))
Authors: J. S. Wei, B. T. Greer, F. Westermann, S. M. Steinberg, C. G. Son, Q. R. Chen, C. C. Whiteford, S. Bilke, A. L. Krasnoselsky, N. Cenacchi, D. Catchpoole, F. Berthold, Manfred Schwab, J. Khan
Journal: Cancer Research (2005)
Evaluation of Combinational Therapy of MDM2-Antagonist Nutlin-3 and HDAC-Inhibitor Valproic Acid in Acute Myeloid Leukemia in Vitro and in Vivo
Authors: Emmet McCormack, Ingvild Haaland, Gurid Venås, Rakel Brendsdal Forthun, Øystein Bruserud, Bjørn Tore Gjertsen
Journal: Blood (2008)
Choices of first-line therapy in her2-ve advanced breast cancer (abc) patients (pts). prelimary results of the gim-13 - ambra study
Authors: M.E. Cazzaniga, G. Mustacchi, M. Giordano, O. Garrone, M. Donadio, L. Del Mastro, L. Livi, C. Natoli, A. Michelotti, A. Turletti, F. Riccardi, P. Paolo, S. De Placido, M. De Laurentiis, P. Marchetti, F. Montemurro
Journal: Annals of Oncology (2016)
Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study
Authors: Michela Rondoni, Daniela Cilloni, Stefania Paolini, Emanuela Ottaviani, Francesca Messa, Pier Paolo Piccaluga, Ilaria Iacobucci, Francesco Buccisano, Mario Tiribelli, Monica Bocchia, Francesco Lauria, Serena Merante, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2008)
Polymorphisms Associated with the Arab-Indian Haplotype of Sickle Cell Anemia Are Candidate Fetal Hemoglobin Gene Modulators
Authors: Vinod Vathipadiekal, Abdulrahman Alsultan, John Farrell, A.M Al-Rubaish, Fahad Al-Muhanna, Z Naserullah, A Alsuliman, P.K. Patra, Jacqueline Milton, Lindsay Farrer, David H.K. Chui, Amein Al-Ali, Paola Sebastiani, Martin H. Steinberg
Journal: Blood (2015)
Impact of VEGF and VEGFR single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine tumors
Authors: A. Savini, M. Torniai, S. Pagliaretta, S. Rinaldi, F. Morgese, M. Caramanti, M. Santoni, S. Onorati, S. Pompili, A. Onofri, R. Berardi
Journal: Annals of Oncology (2016)
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre–B ALL
Authors: Hilde Schjerven, Etapong F. Ayongaba, Ali Aghajanirefah, Jami McLaughlin, Donghui Cheng, Huimin Geng, Joseph R. Boyd, Linn M. Eggesbø, Ida Lindeman, Jessica L. Heath, Eugene Park, Owen N. Witte, Stephen T. Smale, Seth Frietze, Markus Müschen
Journal: The Journal of Experimental Medicine (2017)

Inactivation of the tumor suppressor gene encoding the transcriptional regulator Ikaros (IKZF1) is a hallmark of BCR-ABL1+ precursor B cell acute lymphoblastic leukemia (pre-B ALL). However, the mechanisms by which Ikaros functions as a tumor suppressor in pre-B ALL remain poorly understood. Here, we analyzed a mouse model of BCR-ABL1+ pre-B ALL together with a new model of inducible expression of wild-type Ikaros in IKZF1 mutant human BCR-ABL1+ pre-B ALL. We performed integrated genome-wide chromatin and expression analyses and identified Ikaros target genes in mouse and human BCR-ABL1+ pre-B ALL, revealing novel conserved gene pathways associated with Ikaros tumor suppressor function. Notably, genetic depletion of different Ikaros targets, including CTNND1 and the early hematopoietic cell surface marker CD34, resulted in reduced leukemic growth. Our results suggest that Ikaros mediates tumor suppressor function by enforcing proper developmental stage-specific expression of multiple genes through chromatin compaction at its target genes.
Malignant Gastric Mass in a Patient with Immune Dysregulation, Polyendocrinopathy, Enteritis, X Linked (IPEX)
Authors: Dipika Patel, Caridad Martinez, Stacey Shubert, Filiz O. Seeborg, Sean M. Cullen, Lenora Mendoza Noroski, Lisa R. Forbes, Nicholas Rider
Journal: Journal of Allergy and Clinical Immunology (2017)
Effect of pericytes on melanoma development.
Authors: Jose Humberto Trevino-Villarreal, Douglas A. Cotanche, Rosalinda Sepulveda, Rick A. Rogers
Journal: Journal of Clinical Oncology (2012)

83 Background: Melanoma-associated stroma cells regulate tumor establishment, invasion, and dissemination through paracrine and heterotypic cell-cell interactions with cancer cells. Pericytes constitute a major noninflammatory component of the melanoma-associated stroma. Our study is designed to evaluate the role of pericytes in melanoma development. Methods: Tumors induced in GFP + /SCID mice with GFP - B16 cells were harvested after 14 days, enzyme digested, labeled against mesenchymal markers, and analyzed by flow cytometry (FC). The distribution of stromal subpopulations in tumors was investigated by immunofluorescence microscopy (IFM). Stromal pericytes from tumors and adipose tissue were FACS sorted, mixed with B16 cells at a 3:1 ratio, and injected into SCID mice. Tumor diameters were taken periodically with a scientific caliper, and used to determine tumor volumes using the ellipsoid formula. Results: FC analysis showed that the melanoma stroma was composed of CD45 + inflammatory cells, CD31 + endothelial cells, FAP + myofibroblasts and CD146 + cells. IFM analysis showed that the CD146 + cells are perivascular CD31 - /CD34 - /α-SMA + stromal pericytes that associated with TGF-β immunoreactive CD271 + /CD146 + B16 cells in perivascular tumor niches. Co-induction experiments were performed to investigate the effect of pericytes on melanoma development. We observed faster growth rates in the size of tumors co-induced with pericytes, compared with tumors induced with B16 cells alone. These co-induced tumors had bigger masses, more volume, were hypercellular, and had increase vascularization compared with control tumors. In addition, pericytes increased the B16 cell proliferation rate, as determined by higher expression of Ki-67 in the tumor fraction of co-induced tumors. Conclusions: Pericytes promote melanoma development by inducing angiogenesis and melanoma cell proliferation. Our results suggest that pericytes could be utilized as a therapeutic target for melanoma treatment.
IgA-coated <i>E. coli</i> enriched in Crohn’s disease spondyloarthritis promote T <sub>H</sub> 17-dependent inflammation
Authors: Monica Viladomiu, Charles Kivolowitz, Ahmed Abdulhamid, Belgin Dogan, Daniel Victorio, Jim G. Castellanos, Viola Woo, Fei Teng, Nhan L. Tran, Andrew Sczesnak, Christina Chai, Myunghoo Kim, Gretchen E. Diehl, Nadim J. Ajami, Joseph F. Petrosino, Xi K. Zhou, Sergio Schwartzman, Lisa A. Mandl, Meira Abramowitz, Vinita Jacob, Brian Bosworth, Adam Steinlauf, Ellen J. Scherl, Hsin-Jung Joyce Wu, Kenneth W. Simpson, Randy S. Longman
Journal: Science Translational Medicine (2017)

IgA-reactive E. coli in Crohn’s disease–associated spondyloarthritis link mucosal immunity and systemic inflammation.
Mucosal Type 2 Innate Lymphoid Cells Are a Key Component of the Allergic Response to Aeroallergens
Authors: Jaideep Dhariwal, Aoife Cameron, Maria-Belen Trujillo-Torralbo, Ajerico del Rosario, Eteri Bakhsoliani, Malte Paulsen, David J. Jackson, Michael R. Edwards, Batika M. J. Rana, David J. Cousins, Trevor T. Hansel, Sebastian L. Johnston, Ross P. Walton
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Newly characterized type 2 innate lymphoid cells (ILC2s) display potent type 2 effector functionality; however, their contribution to allergic airways inflammation and asthma is poorly understood. Mucosal biopsy used to characterize the airway mucosa is invasive, poorly tolerated, and does not allow for sequential sampling.To assess the role of ILC2s during nasal allergen challenge in subjects with allergic rhinitis using novel noninvasive methodology.We used a human experimental allergen challenge model, with flow cytometric analysis of nasal curettage samples, to assess the recruitment of ILC2s and granulocytes to the upper airways of subjects with atopy and healthy subjects after allergen provocation. Soluble mediators in the nasal lining fluid were measured using nasosorption.After an allergen challenge, subjects with atopy displayed rapid induction of upper airway symptoms, an enrichment of ILC2s, eosinophils, and neutrophils, along with increased production of IL-5, prostaglandin D2, and eosinophil and T-helper type 2 cell chemokines compared with healthy subjects. The most pronounced ILC2 recruitment was observed in subjects with elevated serum IgE and airway eosinophilia.The rapid recruitment of ILC2s to the upper airways of allergic patients with rhinitis, and their association with key type 2 mediators, highlights their likely important role in the early allergic response to aeroallergens in the airways. The novel methodology described herein enables the analysis of rare cell populations from noninvasive serial tissue sampling.
BMET-19. DEFINING STEREOTACTIC RADIOSURGERY USE PRACTICES FOR BRAIN METASTASES IN THE UNITED STATES
Authors: Hyun Kim, Shivank Garg, Jenny Guo, Ingrid Kalchman, John McAna, Wenyin Shi
Journal: Neuro-Oncology (2016)

Stereotactic radiosurgery (SRS) is an increasingly used modality for the treatment of intracranial metastases. There are currently no established guidelines delineating indications for SRS use or plan evaluation in the treatment of multiple brain metastases. An 18 question electronic survey was distributed to radiation oncologists at National Cancer Institute designated cancer centers in the US (60). Centers without radiation oncologists were excluded. Physicians that indicated that they do not prescribe SRS were not invited to complete the remaining survey questions. Sign test and Chi-square test were used to determine if responses differed significantly from random distribution. One hundred sixteen of the 697 radiation oncologists surveyed completed the questionnaire. Sixty-two percent reported treating patients with brain metastases using SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung (49.3%). SRS was used more frequently for <10 brain metastases (73.7%; p<.0001) and whole brain radiation therapy (WBRT) for >10 brain metastases (82.5%; p<.0001). The maximum amount of lesions physicians were willing to treat with SRS without WBRT was 1-4 (40.4%) and 5-10 (42.4%) (p<.0001 compared to 11-15, 16-20 and no limit). The most important criteria for choosing SRS or WBRT were number of lesions (p<.0001) and performance status (p=.016). The most common margin for SRS was 0 mm (49.1%; p=.0021). The most common dose constraints other than critical structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most common treatment modality (54.4%) and mono-isocenter technique for multiple brain metastases was commonly used (43.9%; p=.23). Most departments do not have a policy for brain metastases treatment (64.9%; p=.024). This is the first national assessment of SRS use practice for brain metastases. These data may guide physicians that are not familiar with SRS treatment and the development of SRS guidelines by cooperative groups.
Phase 1 study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer
Authors: T.W. Laetsch, R. Nagasubramanian, S.G. Dubois, L. Mascarenhas, D. Hawkins, N. Shukla, B. Turpin, S. Smith, M. Reynolds, S. Cruickshank, L. Donahue, M.C. Cox, A. Pappo
Journal: Annals of Oncology (2016)
A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)
Authors: John Grainger, James B. Bussel, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, Nancy Carpenter, Melissa Eisen, Bhakti Mehta
Journal: Blood (2016)
Prognostic Significance of Immunohistochemical Markers in Classical Hodgkin Lymphoma Response to Treatment A Study of 59 Cases.
Authors: Danielle Canioni, Benedicte Deau, Pierre Taupin, Jacques Bosq, Vincent Ribrag, Richard Delarue, Viorel Vasiliu, Nicole Brousse, Olivier Hermine
Journal: Blood (2005)
Association of Gene-Gene Interactions with Venous Thromboembolism (VTE): A Merged/Imputed Genome-Wide Scan/Candidate-Gene Case-Control Study
Authors: John A. Heit, Sebastian M. Armasu, Martha E. Matsumoto, Tanya M. Petterson, David N. Rider, Julie M. Cunningham, Yan W. Asmann, Mariza de Andrade
Journal: Blood (2011)
IL-13-Induced Goblet Cell Antigen Passages (GAP's) are Required for the Acute Onset of a Food-Induced Anaphylactic Reaction
Authors: Taeko Noah, Kathryn Knoop, Keely G. McDonald, Jenny Gustafsson, Lisa Waggoner, Matthew Batie, Maxime Mahe, Michael Helmrath, Rodney Newberry, Simon P. Hogan
Journal: Journal of Allergy and Clinical Immunology (2017)
Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs
Authors: Laurie Herviou, Alboukadel Kassambara, Stephanie Boireau, Nicolas Robert, Guilhem Requirand, Laure Vincent, Anja Seckinger, Hartmut Goldschmidt, Dirk Hose, Giacomo Cavalli, Jerome Moreaux
Journal: Blood (2016)